← Back to Clinical Trials
Recruiting NCT07341503

NCT07341503 The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07341503
Status Recruiting
Phase
Sponsor Ohio State University Comprehensive Cancer Center
Condition Anatomic Stage I Breast Cancer AJCC v8
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2025-08-18
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Non-Interventional Study

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2025-08-18 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is being done to learn more about breast cancer patients' experiences with sleep changes during cancer treatment, identify possible reasons for poor sleep quality, and to find out how stress, social support, and living environment affect sleep.

Eligibility Criteria

Inclusion Criteria: * \* Age \>= 18 years old at time of breast cancer diagnosis * Stage I to III breast cancer diagnosis * Hormone receptor positive breast cancers * Post primary surgery, before chemotherapy/radiation therapy begins * No known evidence of breast cancer recurrence (local or distant) or second, primary cancer * No prior history of new other malignancy since their breast cancer diagnosis (other than non-melanoma skin cancer) * Able to speak, understand and read English * Cognitively able to complete the study requirements * Ability to access medical records from treating hospital Exclusion Criteria: * \* Stage IV or metastatic breast cancer * Not cognitively able to provide informed consent * Not willing to provide informed consent

Contact & Investigator

Central Contact

The Ohio State University Comprehensive Cancer Center

✉ OSUCCCClinicaltrials@osumc.edu

📞 800-293-5066

Principal Investigator

Electra Paskett, MSPH, PhD, FAACR

PRINCIPAL INVESTIGATOR

Ohio State University Comprehensive Cancer Center

Frequently Asked Questions

Who can join the NCT07341503 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Anatomic Stage I Breast Cancer AJCC v8. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07341503 currently recruiting?

Yes, NCT07341503 is actively recruiting participants. Contact the research team at OSUCCCClinicaltrials@osumc.edu for enrollment information.

Where is the NCT07341503 trial being conducted?

This trial is being conducted at Columbus, United States.

Who is sponsoring the NCT07341503 clinical trial?

NCT07341503 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is Electra Paskett, MSPH, PhD, FAACR at Ohio State University Comprehensive Cancer Center. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology